SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1),...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Tuccori, Marco, Baj, Andreina, Maggi, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310233/
https://www.ncbi.nlm.nih.gov/pubmed/34201767
http://dx.doi.org/10.3390/v13071211
_version_ 1783728711232651264
author Focosi, Daniele
Tuccori, Marco
Baj, Andreina
Maggi, Fabrizio
author_facet Focosi, Daniele
Tuccori, Marco
Baj, Andreina
Maggi, Fabrizio
author_sort Focosi, Daniele
collection PubMed
description We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
format Online
Article
Text
id pubmed-8310233
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83102332021-07-25 SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies Focosi, Daniele Tuccori, Marco Baj, Andreina Maggi, Fabrizio Viruses Editorial We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician. MDPI 2021-06-23 /pmc/articles/PMC8310233/ /pubmed/34201767 http://dx.doi.org/10.3390/v13071211 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Focosi, Daniele
Tuccori, Marco
Baj, Andreina
Maggi, Fabrizio
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
title SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
title_full SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
title_fullStr SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
title_full_unstemmed SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
title_short SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
title_sort sars-cov-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310233/
https://www.ncbi.nlm.nih.gov/pubmed/34201767
http://dx.doi.org/10.3390/v13071211
work_keys_str_mv AT focosidaniele sarscov2variantsasynopsisofinvitroefficacydataofconvalescentplasmacurrentlymarketedvaccinesandmonoclonalantibodies
AT tuccorimarco sarscov2variantsasynopsisofinvitroefficacydataofconvalescentplasmacurrentlymarketedvaccinesandmonoclonalantibodies
AT bajandreina sarscov2variantsasynopsisofinvitroefficacydataofconvalescentplasmacurrentlymarketedvaccinesandmonoclonalantibodies
AT maggifabrizio sarscov2variantsasynopsisofinvitroefficacydataofconvalescentplasmacurrentlymarketedvaccinesandmonoclonalantibodies

Ejemplares similares